Lenaerts, C. (2019). Défis et stratégies novatrices pour la quantification de la marinobufagénine : application au syndrome de prééclampsie [Doctoral thesis, Université de Mons]. ORBi UMONS-University of Mons. https://orbi.umons.ac.be/handle/20.500.12907/11041 |
  | Lenaerts, C., Wells, M., Hambye, S., & Blankert, B. (17 January 2019). Marinobufagenin extraction from Rhinella marina toad glands: alternative approaches for a systematized strategy. Journal of Separation Science, 42 (7), 1384 - 1392. doi:10.1002/jssc.201800879  Peer Reviewed verified by ORBi |
Lenaerts, C., Wells, M., Hambye, S., & Blankert, B. (12 September 2018). Quantification of endogenous marinobufagin by a high-specific and very sensitive UPLC-MS/MS assay in non-patological pregnancy and preeclampsia [Paper presentation]. DA-PBA 2018 : 11th International symposium on Drug Analysis - 29th International Symposium on Pharmaceutical and Biomedical Analysis, Leuven, Belgium. Peer reviewed |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (17 May 2018). Revealing of endogenous Marinobufagin by an ultra-specific and sensitive UHPLC-MS/MS assay in pregnant women. Talanta, 187, 193-199. Peer Reviewed verified by ORBi |
Laenens, E., Lenaerts, C., & Blankert, B. (2017). Le venin de crapaud buffle au secours des femmes enceintes. LUMONS - élément. |
Wells, M., Lenaerts, C., & Blankert, B. (2017). Amélioration des techniques d'extraction de la marinobufagénine de matrices complexes [Master’s dissertation, Université de Mons]. ORBi UMONS-University of Mons. https://orbi.umons.ac.be/handle/20.500.12907/9996 |
 | Lenaerts, C., & Blankert, B. (2017). Le venin thérapeutique - Quand le poison devient un remède. |
 | Wells, M., Lenaerts, C., Hambye, S., & Blankert, B. (28 March 2017). Stratégies d'extraction et de purification de la Marinobufagénine à partir du venin du crapaud Bufo marinus [Poster presentation]. 12ème Congrès de l'Association Francophone des Sciences Séparatives, Paris, France. |
 | Lenaerts, C., & Blankert, B. (2017). le venin de crapaud pour diagnostiquer un syndrome préoccupant chez la femme enceinte. |
Blankert, B., & Lenaerts, C. (2017). UMons: vers un diagnostic au venin de crapaud. Groupe Sud Presse. |
 | Lenaerts, C., & Blankert, B. (2017). Intérêt des venins dans le diagnostic thérapeutique. |
Wells, M., Lenaerts, C., Hambye, S., & Blankert, B. (17 October 2016). Extraction and purification strategies of marinobufagenin from bufo marinus toad venom [Paper presentation]. 19th Forum of Pharmaceutical Sciences, Bruxelles, Belgium. |
 | Lenaerts, C., Blankert, B., Bond, L., Tuytten, R., Van Antwerpen, P., & Delporte, C. (17 October 2016). Elaboration of a quantification assay of marinobufagenin in human plasma: a novel approach based on response factor quantification by LC-MS/MS [Paper presentation]. 19th Forum of Pharmaceutical Sciences, Bruxelles, Belgium. |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (15 August 2016). Early prediction of preeclampsia risk assessment: analytical determination for marinobufagenin in pregnant women. Journal of Maternal-Fetal and Neonatal Medicine, 29, 18. Peer Reviewed verified by ORBi |
Lenaerts, C., Tuytten, R., Bond, L., Delporte, C., Van Antwerpen, P., & Blankert, B. (06 July 2016). A LC-MS assay for identification and quantification of marinobufagenin in human: a novel approach for preeclampsia risk evaluation [Paper presentation]. MASCL, Salzburg, Austria. Peer reviewed |
Wells, M., Lenaerts, C., & Blankert, B. (2016). Exploration et perfectionnement des techniques de purification de la Marinobufagénine à partir du venin de Bufo Marinus. |
Lenaerts, C., Tuytten, R., Bond, L., Delporte, C., Van Antwerpen, P., & Blankert, B. (12 May 2016). Early prediction of preeclampsia risk assessment: analytical determination for marinobufagenin in pregnant women [Paper presentation]. Second International Congress on Maternal Hemodynamics, Rome, Italy. Peer reviewed |
Lenaerts, C., Tuytten, R., Bond, L., Delporte, C., Van Antwerpen, P., & Blankert, B. (27 January 2016). Setting up of a LC-MS/MS assay for identification and quantification of MBG in pregnant women for preeclampsia risk evaluation [Poster presentation]. HTC-14 ; 14th International Symposium on Hyphenated Techniques in Chromatography and Separation Technology, Ghent, Belgium. |
Lenaerts, C., & Blankert, B. (15 October 2015). Marinobufagenin as a promising preeclampsia assessment marker [Paper presentation]. Séminaire Hôpital Ambroise Paré, Mons, Belgium. |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (24 September 2015). Marinobufagenin as a promising preeclampsia risk assessment marker: purification from toad venom and LC-MS identification in human plasma [Paper presentation]. ISSHP (International Society for the Study of Hypertension in Pregnancy) 2015, Budapest, Hungary. Peer reviewed |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (13 July 2015). Marinobufagenin as a potential biomarker for preeclampsia risk assessment: purification from Bufo Marinus toad venom as support for a human plasma LC-MS/MS assay [Paper presentation]. Joint meeting of the GP-TCM Research Association, the TCM Chemistry Specialty Committee and the TCM Pharmaceutical Analysis Specialty Committee of the World Federation of Chinese Medicine Societies, Mons, Belgium. Peer reviewed |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (09 July 2015). Marinobufagenin as a promising preeclampsia risk assessment marker: purification from toad venom and LC-MS identification in human plasma. Pregnancy Hypertension, 5 (3), 213-214. Peer reviewed |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (15 May 2015). Marinobufagenin : extraction and LC-MS/MS identification in toad venom and human plasma as a promising preeclampsia risk stratification tool [Poster presentation]. Bioforum 2015- ULG, Liège, Belgium. |
Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (15 May 2015). LC-MS/MS analysis of marinobufagenin in human plasma : an encouraging predictive tool for preeclampsia risk stratification [Paper presentation]. Forum SBSP 2015, Blankenberge, Belgium. |
 | Bond, L., Nolan, C., Hyland, K., Lenaerts, C., Baker, P., Kenny, L., & Tuytten, R. (26 October 2014). PREECLAMPSIA RISK STRATIFICATION EARLY IN PREGNANCY: LEVERAGING A PROMISING METABOLOMICS DISCOVERY INTO A LC-MS BASED CLINICAL ASSAY [Poster presentation]. ISSHP (International Society of the Study of Hypertension in Pregnancy) World Congress, New Orleans, United States - Louisiana. |
 | Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (17 October 2014). Analysis of marinobufagenin in plasma for preeclampsia risk assessment: a promising early predictive tool [Paper presentation]. 1st International Congress on Maternal Hemodynamics, Hasselt, Belgium. Peer reviewed |
 | Bond, L., Lenaerts, C., Benton, C., Baker, P., Kenny, L., & Tuytten, R. (04 September 2014). Preeclampsia risk stratification early in pregnancy: Conversion of a promising metabolomics discovery into a LC-MS based clinical assay [Poster presentation]. MSACL, Salzburg, Austria. |
 | Lenaerts, C., Bond, L., Tuytten, R., & Blankert, B. (03 September 2014). Identification of marinobufagenin in plasma as a promising LC-MS assay for preeclampsia risk assessment [Poster presentation]. MSACL, Salzburg, Austria. |
Lenaerts, C., Deplechin, T., & Blankert, B. (22 June 2014). Set up of a solid phase extraction (SPE) method of marinobufagenin from human plasma [Poster presentation]. Drug Analysis, Liège, Belgium. |
Lenaerts, C., Deplechin, T., & Blankert, B. (13 February 2014). Purification and extraction of marinobufagenin from Bufo Marinus toad venom and from human plasma [Poster presentation]. 6ème Journée Scientifique du Pôle hainuyer, Mons, Belgium. |
 | Lenaerts, C., Demeyer, M., Gerbaux, P., & Blankert, B. (17 October 2013). Challenges and novel strategies for quantification of marinobufagenin within the framework of preeclampsia [Paper presentation]. 17th Forum of Pharmaceutical Sciences, Spa, Belgium. |
 | Lenaerts, C., Larcy, C., & Blankert, B. (13 June 2013). Analytical aspects of marinobufagenin and its applications in the diagnosis of preeclampsia [Poster presentation]. ISSHP (International Society of the Study of Hypertension in Pregnancy) European Congress, Tromso, Norway. |
Lenaerts, C., Larcy, C., & Blankert, B. (01 June 2013). Analytical aspects of marinobufagenin and its applications in the diagnosis of preeclampsia. Pregnancy Hypertension, 3, 99. Peer reviewed |
  | Lenaerts, C., & Blankert, B. (24 May 2013). Marinobufagenin : a new diagnosis target for preeclampsia syndrome? [Poster presentation]. 1st Health Institute Day, Mons, Belgium. |
Lenaerts, C., & Blankert, B. (12 March 2013). Marinobufagenin: a new diagnostic target for preeclampsia syndrome? [Poster presentation]. 7ème édition de la Matinée de Chercheurs, Mons, Belgium. |
Lenaerts, C., Helvenstein, M., & Blankert, B. (29 January 2013). Marinobufagenin and its applications in the diagnosis of preeclampsia [Poster presentation]. Journée scientifique des doctorants en Sciences Biomédicales et Pharmaceutiques: 'New tools and strategies in identification of pathology-related biomarkers', UMONS, Belgium. |
 | Lenaerts, C., Demeyer, M., Gerbaux, P., & Blankert, B. (01 January 2013). Analytical aspects of marinobufagenin. Clinica Chimica Acta, 421, 193-201. Peer Reviewed verified by ORBi |
 | Lenaerts, C., & Blankert, B. (16 October 2012). Analytical aspects of marinobufagenin and its applications in the diagnostic of preeclampsia [Paper presentation]. VIIe PhD Day de l'école doctorale en sciences pharmaceutiques ULB/UMONS, Bruxelles, Belgium. |